報價延遲最少15分鐘:2026/04/22 02:18 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
30.8 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.50/-0.15
|
|
企業價值
1.64B
|
| 資產負債 |
|
每股賬面淨值
-2.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
29.64M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without addingburden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment. |
